Certain human cancers and carcinogen-induced rodent tumors commonly contain Kras2 mutations. This activated form of ras has always been described as a dominant oncogene. A new study indicates that wildtype Kras2 has properties of a tumor suppressor gene and may have the capacity to reduce the transforming potential of oncogenically activated ras.
This is a preview of subscription content, log in via an institution to check access.
References
Reddy, E.P., Reynolds, R.K., Santos, E. & Barbacid, M. Nature 300, 149–152 (1982).
Tabin, C.J. et al. Nature 300, 143–149 (1982).
Bos, J.L. Cancer Res. 49, 4682–4689 (1989).
Johnson, L. et al. Nature 410, 1111–1116 (2001).
Johnson, L. et al. Genes Dev. 11, 2468–2481 (1997).
Zhang, Z. et al. Nature Genet. 29, 25–33 (2001).
Finney, R.E. & Bishop, J.M. Science 260, 1524–1527 (1993).
Borasio, G.D. et al. Neuron 2, 1087–1096 (1989).
Dammann, R. et al. Nature Genet. 25, 315–319 (2000).
Campbell, S.L., Khosravi-Far, R., Rossman, K.L., Clark, G.J. & Der, C.J. Oncogene 17, 1395–1413 (1998).
Stewart, S. & Guan, K.L. J. Biol. Chem. 275, 8854–8862 (2000).
Chang, E.H., Furth, M.E., Scolnick, E.M. & Lowy, D.R. Nature 297, 479–483 (1982).
Bremner, R. & Balmain, A. Cell 61, 407–417 (1990).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pfeifer, G. A new verdict for an old convict. Nat Genet 29, 3–4 (2001). https://doi.org/10.1038/ng0901-3
Issue Date:
DOI: https://doi.org/10.1038/ng0901-3
- Springer Nature America, Inc.
This article is cited by
-
Molecular pathogenesis of MEN2-associated tumors
Familial Cancer (2005)
-
Dr Jekyll and Mr Hyde
Nature Reviews Cancer (2001)